What is hlh

Understanding Hemophagocytic Lymphohistiocytosis

Hemophagocytic Lymphohistiocytosis (HLH) is a rare but serious immune system disorder in which the body's immune cells become excessively activated and attack the body's own cells and tissues. This uncontrolled immune response leads to severe inflammation and multi-organ involvement. HLH is a medical emergency that requires prompt diagnosis and aggressive treatment to prevent fatal outcomes.

Primary vs. Secondary HLH

HLH exists in two main forms. Primary HLH is an inherited genetic disorder present from birth, typically caused by mutations in genes that regulate immune cell function and natural killer cells. Secondary HLH develops in response to infections (particularly viral infections like EBV), malignancies, or autoimmune conditions. Both forms present similarly but may require different treatment approaches, with primary HLH often requiring bone marrow transplantation for cure.

Symptoms and Presentation

Common symptoms of HLH include:

• Persistent high fever that doesn't respond to standard antibiotics
• Hepatosplenomegaly (enlarged liver and spleen causing abdominal pain)
• Lymphadenopathy (swollen lymph nodes throughout the body)
• Low blood cell counts causing anemia, bleeding, and infections
• Rash or skin manifestations indicating immune activity
• Neurological symptoms in severe cases affecting brain function
• Bleeding, bruising, or bleeding from the nose and gums

Pathophysiology

In HLH, cytotoxic T lymphocytes and macrophages become hyperactivated and proliferate uncontrollably. These activated immune cells infiltrate various organs and engulf blood cells and tissue cells in a process called hemophagocytosis. The excessive activation also produces large amounts of inflammatory cytokines, including interferon-gamma and TNF-alpha, leading to widespread inflammation and tissue damage throughout the body.

Diagnosis and Treatment

Diagnosis of HLH requires a combination of clinical criteria and laboratory findings. These include documented fever, splenomegaly, cytopenias, hypertriglyceridemia, low fibrinogen, and elevated ferritin levels. Treatment typically involves chemotherapy agents (particularly etoposide), corticosteroids, and supportive care. For primary HLH, allogeneic hematopoietic stem cell transplantation may be necessary for long-term cure and prevention of recurrence.

Prognosis and Outcomes

Without treatment, HLH is rapidly progressive and often fatal within weeks. However, with prompt diagnosis and appropriate treatment, many patients achieve remission and long-term survival. The prognosis depends on various factors including age, underlying genetic factors, and response to initial therapy. Survival rates have improved significantly with modern treatment protocols, though HLH remains a serious condition requiring specialized medical care.